Rasagiline

A monoamine oxidase (MAO)-B inhibitor (MAOI), is indicated for the treatment of Parkinson?s disease

(MAO)-B inhibitor

Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. The way it acts is related to its MAO-B inhibitory activity, which causes an increase in extracellular levels of dopamine in the striatum. The elevated dopamine level and subsequent increased dopaminergic activity are likely to mediate rasagiline's beneficial effects seen in models of dopaminergic motor dysfunction.

Monotherapy: 1 mg once daily ? As adjunct without levodopa: 1 mg once daily ? As adjunct to levodopa: 0.5 mg once daily. Increase dose to 1 mg daily as needed for sufficient clinical response ? Patients taking ciprofloxacin or other CYP1A2 inhibitors: AZILECT 0.5 mg once daily ? Patients with mild hepatic impairment: 0.5 mg once daily. AZILECT should not be used in patients with moderate or severe hepatic impairment

Concomitant use of meperidine, tramadol, methadone, propoxyphene dextromethorphan, St. John?s wort, cyclobenzaprine, or another (selective or non-selective) MAO inhibitor

monotherapy: flu syndrome, arthralgia, depression, dyspepsia Used as adjunct without levodopa: peripheral edema, fall, arthralgia, cough, and insomnia Used as adjunct to levodopa: dyskinesia, accidental injury, weight loss, postural hypotension, vomiting, anorexia, arthralgia, abdominal pain, nausea, constipation, dry mouth, rash, abnormal dreams, fall, and tenosynovitis

Pregnancy: Based on animal data, may cause fetal harm. Do not use this unless the potential benefit justifies the potential risk to the fetus

Signs and symptoms of Rasagiline overdose may include drowsiness, dizziness, faintness, irritability, hyperactivity, agitation, severe headache, hallucinations, trismus, opisthotonos, convulsions and coma; rapid and irregular pulse, hypertension, hypotension and vascular collapse; precordial pain, respiratory depression and failure, hyperpyrexia, diaphoresis, and cool, clammy skin. Treatment: There is no specific antidote for Rasagiline overdose. The following suggestions are offered: Respiration should be supported by appropriate measures, including management of the airway, use of supplemental oxygen, and mechanical ventilator assistance, as required. Body temperature should be monitored closely. Intensive management of hyperpyrexia may be required. Maintenance of fluid and electrolyte imbalance is essential. For this reason, in cases of overdose with Rasagiline, dietary tyramine restriction should be observed for several weeks to reduce the risk of hypertensive tyramine reaction. Moreover, a poison control center should be called for the most current treatment guidelines.

Store at temperature not exceeding 30ºC in a dry place. Protect from light. Keep out of reach of children. To be sold by retail on the prescription of a registered physician only.

P⊗